Allergan - Database of Clinical Trials by Pharmaceutical Companies

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Allergan

Top of Directory » All Categories » by Company » Allergan



  • Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects

    Condition:   Dry Eye Syndrome
    Interventions:   Drug: Glycerin and Polysorbate 80 based artificial tear;   Drug: Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear;   Drug: Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
    Sponsor:   Allergan
    Not yet recruiting - verified November 2009
  • The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability

    Condition:   Dry Eye Syndrome
    Interventions:   Drug: Optive;   Drug: Soothe;   Drug: New Emulsion
    Sponsors:   Southern California College of Optometry;   Allergan
    Recruiting - verified November 2009
  • Evaluation of Quality of Life and Self-steem After Botox® in Depressed and Non-depressed Patients

    Conditions:   Depression;   Quality of Life
    Intervention:   Drug: Botulinum Toxin Type A - BOTOX
    Sponsors:   Brazilan Center for Studies in Dermatology;   Allergan
    Recruiting - verified October 2009
  • Safety and Efficacy of Three Formulations of AGN 210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

    Condition:   Primary Open-Angle Glaucoma
    Interventions:   Drug: AGN-210669 0.05% ophthalmic solution;   Drug: AGN-210669 0.075% ophthalmic solution;   Drug: AGN-210669 0.1% ophthalmic solution;   Drug: bimatoprost 0.03% ophthalmic solution
    Sponsor:   Allergan
    Not yet recruiting - verified October 2009
  • The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata

    Condition:   Alopecia Areata
    Interventions:   Drug: Botulinum toxin type A;   Drug: Triamcinolone acetonide
    Sponsor:   Siriraj Hospital
    Not yet recruiting - verified October 2009
  • A Comparison of Peak Aqueous Penetration and PEG2 Inhibition of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification

    Condition:   Cataracts
    Interventions:   Drug: Ketorolac Tromethamine 0.45%;   Drug: bromfenac 0.09%;   Drug: nepafenac 0.1%
    Sponsors:   Bucci Laser Vision Institute;   Allergan
    Recruiting - verified October 2009
    • Menu
    Find Paid Clinical Trials